PRESS RELEASES

Date Title View
Toggle Summary Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020
DURHAM, N.C. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10,
View HTML
Toggle Summary Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer
Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise DURHAM, N.C. , June 22, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the
View HTML
Toggle Summary Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series
DURHAM, N.C. , June 18, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Company management, including Mike Sherman , Chief Executive Officer, and Mike
View HTML
Toggle Summary Chimerix to Present at Jefferies Virtual Healthcare Conference
DURHAM, N.C. , May 28, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview and
View HTML
Toggle Summary Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update
DSTAT Explored as a Potential Novel Treatment for the Current Pandemic While an NDA is Being Prepared for Brincidofovir to Address a Potential Future Pandemic  DURHAM, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development
View HTML
Toggle Summary Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study Mechanisms of Action May Address Overactive Inflammatory Response, Including Underlying Causes of Blood Coagulation Disorders Associated with COVID-19 Company to Host Conference Call Today at 8:30 a.m.
View HTML
Toggle Summary Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
DURHAM, N.C. , April 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S.
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 40th Annual Health Care Conference
DURHAM, N.C. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview at the
View HTML
Toggle Summary Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update
- Successful DSTAT End of Phase 2 Meeting with FDA Confirms Phase 3 Readiness; First Patient Visit Expected mid-2020 in 1L AML - - Brincidofovir pre-NDA Meeting Scheduled with FDA, on Track for mid-2020 NDA Filing - – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Feb.
View HTML
Toggle Summary Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
DURHAM, N.C. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Pratik S. Multani , M.D., to its Board of Directors, effective
View HTML